Recombinant gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein‐Barr Virus Vaccine in Healthy Young Adults
Open Access
- 15 December 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 196 (12), 1749-1753
- https://doi.org/10.1086/523813
Abstract
Background. To date, there is no commercially available vaccine to prevent infectious mononucleosis, a disease frequently induced by Epstein-Barr virus (EBV) infection in adolescents or adults devoid of preexisting immunity to the virus. Methods. A total of 181 EBV-seronegative, healthy, young adult volunteers were randomized in a double-blind fashion to receive either placebo or a recombinant EBV subunit glycoprotein 350 (gp350)/aluminum hydroxide and 3-O-desacyl-4′-monophosphoryl lipid A (AS04) candidate vaccine in a 3-dose regimen. Results. The vaccine had demonstrable efficacy (mean efficacy rate, 78.0% [95% confidence interval {CI}, 1.0%–96.0%]) in preventing the development of infectious mononucleosis induced by EBV infection, but it had no efficacy in preventing asymptomatic EBV infection. One month after receipt of the final dose of gp350 vaccine, 98.7% of subjects showed seroconversion to anti-gp350 antibodies (95% CI, 85.5%–97.9%), and they remained anti-gp350 antibody positive for >18 months. Furthermore, there were no concerns regarding the safety or reactogenicity of the gp350/AS04 vaccine. Conclusion. These data support the clinical feasibility of using an EBV vaccine to prevent infectious mononucleosis. Trial registration. ClinicalTrials.gov identifier: NCT00430534.Keywords
This publication has 12 references indexed in Scilit:
- Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein–Barr virus vaccine in healthy adultsVaccine, 2007
- A Cohort Study among University Students: Identification of Risk Factors for Epstein‐Barr Virus Seroconversion and Infectious MononucleosisClinical Infectious Diseases, 2006
- Infectious mononucleosis and risk for multiple sclerosis: A meta‐analysisAnnals of Neurology, 2006
- Medical Mystery: Abdominal Pain — The AnswerThe New England Journal of Medicine, 2005
- Stress-associated changes in the steady-state expression of latent Epstein–Barr virus: Implications for chronic fatigue syndrome and cancerBrain, Behavior, and Immunity, 2005
- Characteristics of Hodgkin's Lymphoma after Infectious MononucleosisThe New England Journal of Medicine, 2003
- Lymphoproliferation in Children After Liver TransplantationJournal of Pediatric Gastroenterology and Nutrition, 2002
- INDICATIONS AND RESULTS OF CHEMOTHERAPY IN CHILDREN WITH POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE AFTER LIVER TRANSPLANTATION1Transplantation, 2000
- Expression of Epstein–Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccineVaccine, 1999
- Prevention of Epstein-Barr (EB) Virus-induced Lymphoma in Cottontop Tamarins by Vaccination with the EB Virus Envelope Glycoprotein gp340 Incorporated into Immune-stimulating ComplexesJournal of General Virology, 1988